PBMC viability degrades measurably after 4 to 6 hours from collection. Industry-standard centralized processing routes samples through 18 to 24 hour transit to the processor lab. The math does not work. Clinical trials that protect PBMC viability do one of two things: process samples on-site at each clinical location (expensive and inconsistent across sites), or use a decentralized processor with co-located labs near trial site epicenters that compress the receipt-to-processing window into minutes, not hours.
The viability window in actual hours
PBMCs are not stable indefinitely after collection. Published cell therapy literature and standard QC criteria typically require:
- Time from blood draw to processing: ideally under 6 hours, with measurable viability decline beyond that
- Time from processing to cryopreservation: under 4 hours after isolation
- Total post-collection window before quality is at risk: 4 to 6 hours typically considered the operational ceiling
Centralized cell processing CDMOs (the dominant industry model) require samples to ship by air or ground from the clinical site to the processor’s regional facility. Industry-standard transit time is 18 to 24 hours. By the time samples arrive, the viability window has been violated. Some samples still pass QC. Some don’t. The variability is the problem.
The two architectures that protect viability
Architecture 1: Site-based processing Each clinical trial site has its own processing capability. Local lab, local SOPs, local QC. Pros: short transit. Cons: inconsistent across sites (different operators, different equipment, different protocol drift), expensive at scale (every site needs cleanroom and QC), regulatory burden (each site lab needs its own quality system). For multi-site trials with 5+ locations, this rarely scales. Architecture 2: Decentralized regional processing A single cell processor operates multiple co-located labs near clinical trial epicenters. Samples travel by ground transport (drive time, 30–120 minutes) instead of air shipment. Receipt to processing initiation: 30 minutes. Total draw-to-processed time: typically 150 minutes. Compared to centralized 18 to 24 hours, this is 7 to 10x faster. One quality system across all labs preserves consistency. Multiple sites get covered without each one running its own lab.
OrganaBio runs Clinical Processing Centers in Miami, Irvine, Hayward, and San Diego, with Chicago coming June–July 2026. Average sample receipt-to-processing initiation: 30 minutes. Average draw-to-processed time across 1,400+ clinical samples: 150 minutes. Post-thaw PBMC viability average across 2,500+ samples: 99.1%. The architecture is decentralized, the quality system is unified.
What sponsors should ask before selecting the cell processor
For any cell therapy clinical trial with PBMC samples in the protocol, sponsors should require their cell processor to answer:
- What is your average draw-to-processed time, measured across all samples in the last 12 months? Show me the data, not the marketing claim.
- How many co-located processing labs do you operate, and where are they relative to my trial sites?
- What is your post-thaw viability average, in real numbers, across N samples?
- What happens when a sample arrives outside the viability window? What is the deviation rate?
- How do you maintain quality system consistency across multiple processing sites?
These are the questions that surface whether a processor’s architecture actually protects viability or whether they are running the centralized model and accepting the variability.
Schedule a 30-minute scoping call. We will walk through your specific program needs and where OrganaBio fits.
